We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Nuromol, a medicine that contains 200mg of ibuprofen and 500mg of paracetamol per tablet will become available without the need to visit a pharmacy
Changes to Misuse of Drugs Regulations mean that appropriately qualified nurses and pharmacists will now be able to prescribe controlled drugs like morphine, diamorphine and prescription-strength co-codamol, the Government announced today.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Recordati Rare Diseases T/A Recordati Rare Diseases UK Ltd has made the MHRA aware that specific batches of Pedea 5 mg/ml solution for injection have been packaged with the incorrect Product Information Leaflet (PIL).
Pregabalin has been associated with infrequent reports of severe respiratory depression, including some cases without the presence of concomitant opioid medicines. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment; those using concomitant central nervous system (CNS) depressants;...
Home Secretary seeks expert advice to tighten restrictions on brorphine and metonitazene.
First published during the 2015 to 2016 Cameron Conservative government
Priti Patel commissions the ACMD to tighten the restrictions on three substances under the Misuse of Drugs Act
A summary of recent letters and notifications sent to healthcare professionals about medicines.
Pfizer Ltd are recalling batch number DD4842 as a precautionary measure due to the identification of a nitrosamine above the acceptable limit.
The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to review the harms of Xylazine and 2-Methyl-AP-237.
Leading scientists at Dstl have made an exciting new discovery in the fight against some of the world’s deadliest diseases.
Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone. Furthermore, a significant risk of serious and life-threatening...
Co-proxamol's phased withdrawal period lasts until the end of 2007 to enable patients to move to suitable alternatives.
Safety review initiated following post-surgical fatalities in ultra-rapid metabolisers
SSRIs and SNRIs are known to increase bleeding risks due to their effect on platelet function. Data from observational studies suggest that the use of SSRI/SNRI antidepressants during the month before delivery may result in a small increased risk of...
We have introduced pack size restrictions, revised recommended ages for use, and new safety warnings for over-the-counter stimulant laxatives (orally and rectally administered) following a national safety review. Advise patients that dietary and lifestyle measures should be used first-line for...
Prescribers and dispensers should use caution if switching patients between different long-acting formulations of methylphenidate (Concerta XL, Medikinet XL, Equasym XL, Ritalin LA, and generics) as different instructions for use and different release profiles may affect symptom management.
Pfizer Limited are recalling all batches of Accupro 5mg, 10mg, 20mg, 40mg film-coated tablets as a precautionary measure
Eleven more lethal substances to be made Class A drugs, following a recommendation by the Advisory Council on the Misuse of Drugs.
Findings from research by the MHRA have been published, evaluating two different approaches to cancer therapies which harness the immune system to determine which better targets cancer cells and would reduce side effects for patients.
Rosemont Pharmaceuticals Limited has informed the MHRA that the Press In Bottle Adaptor (PIBA) supplied with the pack (carton) of a specific batch is too wide to fit the neck of the medicine bottle.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).